Comparative Fasting Bioavailability of Dispersible and Conventional Tablets of Risperidone: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Male Chinese Volunteers

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages 1432-1439

  Huang, Mingzhu ^a   Shen Tu, Jianzhong ^a   Hu, Xingjiang ^a   Chen, Junchun ^a   Liu, Jian ^a   Wu, Lihua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

9 hydroxyrisperidone; Bioequivalence; Dispersible tablet; LC MS MS; Pharmacokinetics; Risperidone

Indexed keywords

DRUG METABOLITE; PALIPERIDONE; RISPERIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TABLET;

ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; MALE; RISPERIDONE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TABLETS;

EID: 84862121846     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.027     Document Type: Article

References (27)

1. Xiang Q., Zhao X., Zhou Y., et al. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010, 50:659-666.
2. Lostia A.M., Mazzarini L., Pacchiarotti I., et al. Serum levels of risperidone and its metabolite 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit 2009, 31:475-481.
3. Love R.C., Nelson M.W. Pharmacology and clinical experience with risperidone. Expert Opin Pharmacother 2000, 7:1441-1453.
4. Yasui-Furukori N., Mihara K., Kondo T., et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003, 43:122-127.
5. Pajonk F.G., Schreiner A., Peters S., et al. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. J Clin Psychopharmacol 2005, 25:293-300.
6. Wang L., Yu L., Zhang A.-P., et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007, 21:837-842.
7. Marino J., Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 2008, 28:1283-1298.
8. Chwieduk C.M., Keating G.M. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010, 70:1295-1317.
9. Sastry S.V., Nyshadham J.R., Fix J.A. Recent technological advances in oral drug delivery a review. Pharm Sci Technol Today 2000, 3:138-145.
10. Robinson J.R. Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems. Controlled Drug Delivery-Fundamentals and Actions 1987, 3-94. Marcel Dekker, New York, NY. V.H. Lee (Ed.).
11. Van Schaick E.A., Lechat P., Remmerie B.M., et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther 2003, 25:1687-1699.
12. Cho H.-Y., Lee Y.-B. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res 2006, 29:525-533.
13. Rodrigues Belotto K.C., Barbosa Raposo N.R., Siqueira Ferreira A., et al. Relative bioavailability of two oral formulations of risperidone 2 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. Clin Ther 2010, 32:2106-2115.
14. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects World Medical Association, Accessed March 26, 2006. http://www.wma.net/en/30publications/10policies/b3/index.html.
15. Note for Guidance on Good Clinical Practice. ICH topic E 6 (R1) European Medicines Agency (EMEA), Accessed March 26, 2006. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf.
16. Guideline for Good Clinical Practice [in Chinese] State Food and Drug Administration, Accessed March 5, 2009. http://www.sda.gov.cn/WS01/CL0053/24473.html.
17. Guideline for bioavailability and bioequivalence studies of generic drug products [in Chinese] State Food and Drug Administration, Center for Drug Evaluation, Accessed March 5, 2009. http://www.cde.org.cn/zdyz.do?ethod=largePage&id=2066.
18. Zhou Z.-L., LI H.-D. Advance in search for pharmacokinetics of an atypical antipsychotic: risperidone [in Chinese]. Chin J Clin Pharmacol 2004, 20:228-233.
19. Cabovska B., Cox S.L., Vink A.A. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J Chromatogr B 2007, 852:497-504.
20. Guidance for Industry: Bioanalytical Method Validation US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Accessed March 3, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm70107.pdf.
21. Chen Z.Y., Zheng Q.S., Sun R.Y. Functions of the DAS software for pharmacological calculation. Chin J Clin Pharmacol Ther 2002, 7:562-564.
22. Approval of Supplemental New Drug Application 21-066/S-011 US Food and Drug Administration, Accessed September 6, 2007. http://www.fda.gov/cder/foi/Appletter/2006/O21066s01lltr.pdf.
23. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations Center for Drug Evaluation and Research, US Food and Drug administration, Accessed January 30, 2009. http://www.fda.gov/cder/guidance/5356ful.pdf.
24. Dolder C., Nelson M., Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm 2008, 65:403-413.
25. Fowler J.A., Bettinger T.L., Argo T.R. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther 2008, 32:231-248.
26. Boonleang J., Pipatrattanaseree W., Tanthana C., et al. Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: a single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. Clin Ther 2010, 32:1842-1853.
27. Fang J., Bourin M., Baker G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmiedebergs Arch Pharmacol 1999, 359:147-151.